G&E Herbal Biotechnology Co., Ltd. (4911) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for G&E Herbal Biotechnology Co., Ltd. (4911:TWSE), powered by AI.

Current Price
$31.40
Sector
Healthcare
What is the G&E Herbal Biotechnology Co., Ltd. stock price forecast?

G&E Herbal Biotechnology Co., Ltd. is currently trading at $31.40. View real-time AI analysis on Alpha Lenz.

What is G&E Herbal Biotechnology Co., Ltd. insider trading activity?

View the latest insider trading data for G&E Herbal Biotechnology Co., Ltd. on Alpha Lenz.

What is G&E Herbal Biotechnology Co., Ltd.'s P/E ratio?

View G&E Herbal Biotechnology Co., Ltd.'s valuation metrics on Alpha Lenz.

G&E Herbal Biotechnology Co., Ltd.

TWSE · 4911
NT$31.40+0.05(+0.16%)
Ask about G&E Herbal Biotechnology Co., Ltd.'s future dividend policy...
Alpha Chat Insight

G&E Herbal Biotechnology Co., Ltd.'s ROE is 15.8%. Explore profitability and growth together.

Ask for details

Company Overview

G&E Herbal Biotechnology Co., Ltd. is a biotechnology company specializing in the development, manufacture, and commercialization of novel botanical drugs, western and herbal medicines, and biotechnological services. Founded in 2002 and headquartered in Tainan, Taiwan, the company operates within the health technology sector, with a particular focus on pharmaceuticals and botanical extraction technologies. Its product portfolio includes hepatic protective agents, botanical anti-aging cosmetics, healthcare supplements, topical gels, and lubricants, serving the health and personal care needs of a diverse customer base. G&E Herbal Biotechnology is notable for integrating proprietary botanical extraction processes with clinical research, including ongoing trials for potential treatments targeting conditions such as liver and prostate diseases, and various cancers. By controlling the full supply chain—from contracted cultivation of plant materials to regulated processing—the company ensures traceability and quality in its botanical offerings. With a lean team of approximately 39 employees, G&E Herbal Biotechnology holds a respected position in Taiwan’s life sciences sector, contributing to the advancement of plant-based healthcare and pharmaceutical innovation.

CEOMr. Kou-Wha Kou Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees39

Company Statistics

FY 2025

Profile

N/AMarket Cap
NT$309.13MRevenue
0.00Shares Out
39Employees

Margins

85.15%Gross
54.68%EBITDA
49.27%Operating
51.24%Pre-Tax
45.03%Net

Valuation

N/AP/E
N/AP/B
N/AEV/Sales
N/AEV/EBITDA
N/AP/FCF

Growth (CAGR)

68.51%Rev 3Yr
61.39%Rev 5Yr
202.80%Op Inc 3Yr
N/AOp Inc 5Yr
166.18%Net Inc 3Yr
N/ANet Inc 5Yr

Returns

14.39%ROA
15.80%ROE
16.38%ROIC

Financial Health

NT$78.41MCash & Cash Equivalents
NT$-31.27MNet Debt
5.08%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

G&E Herbal Biotechnology Co., Ltd. (ticker: 4911) is a company listed on TWSE in the Healthcare sector (Biotechnology). It has approximately 39 employees.

The current price is 31.4 with a P/E ratio of -x and P/B of -x.

ROE is 15.80% and operating margin is 49.27%. Annual revenue is $309M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
G&E Herbal Biotechnology Co., Ltd. (4911) Stock Forecast 2026 $31.40 — Price, Financials & Analyst Targets | Alpha Lenz